
Our pick · Oct 2026
Embody
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
- LegitScript certified
Our pick is a commercial choice. We may earn a commission when you join.
Does Alaska Medicaid cover GLP-1s for weight loss?
If you are an adult and weight loss is your only reason, Alaska Medicaid does not cover a GLP-1.
If one of the uses below applies to you, your prescriber can ask Alaska Medicaid to cover that drug. Read the rule and its criteria.
Which drugs Alaska Medicaid covers, and for what:
We checked 4 official documents on October 15, 2026. This is information, not medical advice or a benefit decision.
7 programs that serve Alaska publish a complete monthly price, from $49 at Embody to $297 at Direct Meds GLP-1.

Our pick · Oct 2026
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Our pick is a commercial choice. We may earn a commission when you join.
Some programs are affiliate partners, and we may earn a commission if you join through our link. Payment never moves a row. How we rank

Compounded semaglutide · 12-mo prepay
$588 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
$588 upfront for 12 months of semaglutide. Yearly-plan sale ends December 1; confirm renewal. Paid terms are normally non-refundable; provider-determined medical disqualification allows a refund for the unused term, less services already provided.
The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.
We checked this price on Oct 27, 2026.
Full review and sources
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Fair: 7.3/10 · Compounded
Checked Jul 18, 2026; few independent reviews yet.
$1,188 paid once for the 12-month semaglutide plan; does not renew. Separate monthly subscription: $99 first, then $165. Confirm how four-week vial supplies cover the billing term.
12-month semaglutide one-time plan: $1,188 paid up front, with no renewal. Separate monthly Subscribe and Save is $99 for the first month, then $165. Product pages describe four-week vials; confirm supply coverage across the selected billing term.
We checked this price on Sep 3, 2026.
Full review and sources
Compounded semaglutide · 12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.8/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
12-month compounded semaglutide plan: $1,188 billed every 12 months. The shortest plan is $149 every 4 weeks; plans renew until cancelled Compounded Semaglutide (12-month plan): $99 monthly equivalent; $1,188 billed every 12 months. Provider review, medication and shipping included; prescription required; treatment only if clinically appropriate. Checked October 5, 2026. Consultation: included. Shipping: free. The $99/mo semaglutide rate requires $1,188 upfront for 12 months; the shorter $149 plan bills every 4 weeks, not once per calendar month
We checked this price on Oct 5, 2026.
Full review and sources
Compounded semaglutide lozenge · auto-refill
Advertised program price, not an insurance copay.
Fair: 6.5/10 · Compounded
Checked Oct 16, 2026.
as low as, auto-refill
We checked this price on Oct 2, 2026.
Full review and sources$99/mo equivalent at Trimi Health
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Jul 2, 2026.
$1,188 upfront for 12 months; applicable taxes may add to the bill 12-month prepay: $1,188 upfront ($99 monthly equivalent); does not auto-renew. The separate month-to-month semaglutide plan is $175
We checked this price on Oct 20, 2026.
Full review and sources$212/4 weeks equivalent at Enhance MD

48-week prepay
Advertised program price, not an insurance copay.
Excellent: 9.4/10 · Compounded
Checked Oct 16, 2026; some details not published.
Semaglutide 12-month plan rate, billed every 48 weeks. Shortest plan: $249 every 4 weeks. Confirm the upfront total and any discount.
$212 advertised four-week equivalent on the prepaid 48-week plan, not a calendar-year subscription; shortest plan is $249 billed every 4 weeks
We checked this price on Aug 28, 2026.
Full review and sourcesfrom$297/mo at Direct Meds GLP-1

Confirm the full bill
Advertised program price, not an insurance copay.
Good: 7.5/10 · Compounded
Checked Oct 16, 2026.
Confirm the current prescribed treatment and full bill with the provider.
We checked this price on Sep 3, 2026.
Full review and sources3 more programs serve Alaska without one complete monthly price: Collective, Maximus and Wellorithm. Compare their terms in the price index.
We left out 28 programs whose service-area list has a caveat for Alaska or is incomplete, so confirm your address at intake.
A program that serves Alaska still decides whether to prescribe. Before enrolling, confirm whether it accepts your Medicaid plan and whether your prescribed treatment is covered. The advertised cash prices are not insurance copays. Most listed programs sell compounded semaglutide or tirzepatide, which is not FDA-approved. Check a compounded provider before you pay.
Here is our summary of the Alaska Medicaid rules we checked, with their criteria and limits.
Alaska Medicaid covers Wegovy only to lower heart risk or treat MASH and Zepbound only for sleep apnea, not GLP-1 medicines for weight control, under the state's semaglutide and tirzepatide clinical criteria updated September 18, 2026. Alaska Medicaid can approve Wegovy injection or tablets if you have a BMI of 25 or more and a documented past heart attack, stroke, chronic ischemic heart disease, peripheral artery disease or atherosclerosis. It can also approve Wegovy injection, not the tablet, if you have MASH, a fatty liver disease, with F2 or F3 fibrosis. It approves Zepbound only if a sleep study confirms moderate to severe obstructive sleep apnea and you have a BMI of 30 or more. A first approval lasts up to 3 months, and a renewal up to 12 months. Alaska Medicaid does not list Saxenda or Foundayo on its preferred drug list. Ask your prescriber to send the chart notes these criteria require; Alaska Medicaid still decides each request.
A drug on the preferred list is not covered for every use, so check the rule for yours. A weight-loss exclusion leaves diabetes and other medical requests to their own rules.
We checked Alaska Medicaid clinical criteria: semaglutide (Ozempic, Wegovy), updated September 18, 2026 on October 15, 2026.
We checked Alaska Medicaid clinical criteria: tirzepatide (Mounjaro, Zepbound), updated September 18, 2026 on October 15, 2026.
We checked Alaska Department of Health prior authorization medication list on October 15, 2026.
We checked Alaska Medicaid preferred drug list, effective June 1, 2026 on October 15, 2026.
Call your Medicaid plan, Medicare drug plan or private insurer with these questions, and keep the reference number for each call.
Before you pay cash, confirm:
An “insurance accepted” badge does not tell you your benefit, so ask your plan how its review works.
Your prescriber sends Alaska Medicaid a request with the records that show you meet the rule for your drug and diagnosis, and Alaska Medicaid decides.
What Alaska Medicaid's own criteria ask for, from the documents we read:
What your prescriber usually sends:
Your prescriber works from these Alaska Medicaid documents:
Your prescriber's office files the request; you cannot file it yourself. If Alaska Medicaid says no, ask for the reason in writing, because the notice tells you how to ask for a review and by when.
Medicare's GLP-1 Bridge follows federal rules in every state, so Alaska Medicaid's policy does not decide your Medicare benefit.
We checked CMS's Bridge guidance for Part D plans on September 26, 2026.
Two free official services can help you, and we earn no commission from either.
Alaska Medicaid covers Wegovy only to lower heart risk or treat MASH and Zepbound only for sleep apnea, not GLP-1 medicines for weight control, under the state's semaglutide and tirzepatide clinical criteria updated September 18, 2026.
Alaska Medicaid can approve Wegovy injection or tablets if you have a BMI of 25 or more and a documented past heart attack, stroke, chronic ischemic heart disease, peripheral artery disease or atherosclerosis. It can also approve Wegovy injection, not the tablet, if you have MASH, a fatty liver disease, with F2 or F3 fibrosis. It approves Zepbound only if a sleep study confirms moderate to severe obstructive sleep apnea and you have a BMI of 30 or more. A first approval lasts up to 3 months, and a renewal up to 12 months. Alaska Medicaid does not list Saxenda or Foundayo on its preferred drug list. Ask your prescriber to send the chart notes these criteria require; Alaska Medicaid still decides each request. Before you pay, confirm your exact drug, your diagnosis, any age rules and your plan's authorization steps.
Yes.
Medicare's GLP-1 Bridge follows federal eligibility rules in every state, not Alaska Medicaid's policy. Your ordinary Part D coverage depends on your prescription and your drug plan, and the Bridge runs its own eligibility and authorization review.
Yes, from 10 online programs that publish a service area including Alaska.
At intake, confirm your address, the exact medication and any pharmacy limits, because a state listing does not guarantee you a prescription or a delivery date.
Among programs that serve Alaska, the lowest complete monthly price we found is $49 at Embody.
Across the 10 compounded programs we track nationally, the median advertised recurring price is $124/mo, from $49 to $299. That national figure is not a measured Alaska average, insurance copay or quote for your dose.
Affiliate partners we feature. We may earn a commission.
Check the medication, commitment and total price for your selected plan.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.